Huadong Pharmaceutical announced on the evening of October 18 that Huadong, a wholly-owned subsidiary, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The HDM2006 clinical trial application submitted by China and the US East China was approved, agreeing to carry out clinical trials of this product for advanced solid tumors.

Zhitongcaijing · 10/18 08:33
Huadong Pharmaceutical announced on the evening of October 18 that Huadong, a wholly-owned subsidiary, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The HDM2006 clinical trial application submitted by China and the US East China was approved, agreeing to carry out clinical trials of this product for advanced solid tumors.